Journal
CLINICAL BIOCHEMISTRY
Volume 34, Issue 7, Pages 537-541Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0009-9120(01)00265-X
Keywords
sialic acid; serum; tumor markers; bile duct; cancer; cholangiocarcinoma; ROC analysis
Categories
Ask authors/readers for more resources
Objectives: This study was undertaken to establish the diagnostic utility of serum total sialic acid (TSA) for patients with cholangiocarcinoma (CCA). Design and methods: Serum TSA was determined in 89 histologically confirmed CCA patients, 38 with benign hepatobiliary diseases (BHD) and 43 healthy persons. To check whether the test could adequately discriminate between these groups, complete statistical Receiver Operating Characteristic (ROC) curves were analyzed. Results: The mean value of serum TSA in CCA patients (2.75 0.67 rnmol/L) was significantly higher than that in the BHD (2.33 +/- 0.69 nunol/L p < 0.002) and healthy persons (1.89 +/- 0.46 mmoL/L p < 0.001) groups. The areas under the ROC curves were 0.6699 and 0.8558, respectively. A cut-off value of 2.33 mmol/L discriminated between the CCA, BHD and healthy groups with a sensitivity of 71.9% and a positive predictive value range of 80 to 89%. Conclusion: Determination of TSA yielded high diagnostic values for differentiating between CCA, BHD and healthy persons. The determination of serum TSA would be most useful as an adjunct diagnosis rather than an early detection and screening tool because of the apparent nonspecificity of SA to a given disease. (C) 2001 The Canadian Society of Clinical Chemists. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available